How could the PMPRB's 2025 Annual Report affect the House of Commons' oversight role?
PMPRB tables report detailing high Canadian medicine prices The Patented Medicine Prices Review Board tabled its 2025 Annual Report, which reviews trends in patented medicine prices and sales in Canada. This formal tabling initiates the PMPRB's oversight relationship with the House of Commons, providing the legislative body with specific data on pharmaceutical trends and pricing for review.
- Effect
- Mixed
- How direct
- Stated in the reporting
- When
- Right away
- The story
- No new developments lately
How it reaches House of Commons
-
The Patented Medicine Prices Review Board tabled its 2025 Annual Report, which reviews trends in the prices and sales of patented medicines in Canada. The report noted that sales of patented medicines reached $24.4 billion in 2025, representing 48% of all medicine sales in Canada. In 2025, 1,086 patented medicines for human use were reported to the board.
The full event1independent outlet -
The report, which includes findings that Canadian list prices were third highest among the PMPRB11 countries and seventh highest among 35 OECD countries, is formally tabled with the House of Commons. This action establishes a formal oversight relationship between the PMPRB and the legislative body.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- brantfordexpositor.ca Friday
-
lower house of the Canadian Parliament
Everything about House of Commons
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Sales of patented medicines in Canada were $24.4 billion in 2025brantfordexpositor.ca
- Canadian list prices were third highest amongst the PMPRB11 countriesbrantfordexpositor.ca
- Canadian prices ranked seventh highest among the 35 Organization for Economic Co-operation and Development (OECD) countriesbrantfordexpositor.ca
- Rights holders reported $1.73 billion in R&D expenditures in 2025brantfordexpositor.ca
Why it matters
The PMPRB's mandate is to protect Canadians from patent abuse related to excessive prices. The findings in the 2025 Annual Report, such as the high ranking of Canadian list prices, provide concrete data points that inform the scope and focus of legislative oversight. This data is critical for understanding the economic landscape of pharmaceutical consumption in Canada.
The House of Commons, as a key legislative body, uses these reports to monitor government activity and policy effectiveness. The formal tabling of the report ensures that the legislative branch is aware of the state of patented medicine pricing, allowing for potential debate or policy adjustments regarding drug costs.
What we don't know yet
- What specific policy actions might the House of Commons take based on the report's findings?
- How will the government respond to the PMPRB's findings regarding high Canadian list prices?
Is this still moving?
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- brantfordexpositor.caFriday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.